WO2025158420 - METHODS AND COMPOSITION FOR INDUCING ACTIVATION AND DNA EXPRESSION IN T-CELLS
National phase entry is expected:
Publication Number
WO/2025/158420
Publication Date
31.07.2025
International Application No.
PCT/IB2025/050904
International Filing Date
27.01.2025
Title **
[English]
METHODS AND COMPOSITION FOR INDUCING ACTIVATION AND DNA EXPRESSION IN T-CELLS
[French]
MÉTHODES ET COMPOSITION POUR INDUIRE L'ACTIVATION ET L'EXPRESSION D'ADN DANS DES LYMPHOCYTES T
Applicants **
NANOCELL THERAPEUTICS HOLDINGS B.V.
Inventors
NARAYANAVARI, Suneel
Priority Data
63/625,120
25.01.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6844 | |
| EPO | Filing, Examination, Granting | 166576 | |
| Japan | Filing, Examination, Granting | 5142 | |
| South Korea | Filing, Examination, Granting | 10424 | |
| USA | Filing, Examination, Granting | 54040 |
Total:
243,026
Contact Us
Abstract[English]
The disclosure relates to nanoparticles comprising a surface-exposed immune cell binding moiety, a transposable element comprising a gene sequence flanked by inverted terminal repeats (ITRs), a nucleic acid encoding a transposase with specificity for the ITRs, and an mRNA encoding a first chimeric antigen receptor (CAR) or T-cell receptor (TCR). Methods are also described for treating a disease or disorder by administering such nanoparticles to a subject in need thereof.[French]
La divulgation concerne des nanoparticules comprenant une fraction de liaison de cellule immunitaire exposée en surface, un élément transposable comprenant une séquence génique flanquée par des répétitions terminales inversées (ITR), un acide nucléique codant pour une transposase ayant une spécificité pour les ITR, et un ARNm codant pour un premier récepteur antigénique chimérique (CAR) ou un récepteur de lymphocyte T (TCR). L'invention concerne également des méthodes de traitement d'une maladie ou d'un trouble par administration de telles nanoparticules à un sujet en ayant besoin.